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Evaluation of a multidisciplinary lipid clinic
to improve the care of individuals with
severe lipid conditions: a RE-AIM
framework analysis
Laney K. Jones1,2* , Megan McMinn1, David Kann3, Michael Lesko3, Amy C. Sturm1, Nicole Walters1, Nan Chen4,
Kerrianne Fry1, Ross C. Brownson5,6, Samuel S. Gidding1, Marc S. Williams1 and Alanna Kulchak Rahm1

Abstract
Background: Individuals with complex dyslipidemia, or those with medication intolerance, are often difficult to
manage in primary care. They require the additional attention, expertise, and adherence counseling that occurs in
multidisciplinary lipid clinics (MDLCs). We conducted a program evaluation of the first year of a newly implemented
MDLC utilizing the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework to provide
empirical data not only on program effectiveness, but also on components important to local sustainability and
future generalizability.
Methods: The purpose of the MDLC is to increase the uptake of guideline-based care for lipid conditions.
Established in 2019, the MDLC provides care via a centralized clinic location within the healthcare system. Primary
care providers and cardiologists were invited to refer individuals with lipid conditions. Using a pre/post-study
design, we evaluated the implementation outcomes from the MDLC using the RE-AIM framework.
Results: In 2019, 420 referrals were made to the MDLC (reach). Referrals were made by 19% (148) of the 796 active
cardiology and primary care providers, with an average of 35 patient referrals per month in 2019 (SD 12) (adoption).
The MDLC saw 83 patients in 2019 (reach). Additionally, 50% (41/82) had at least one follow-up MDLC visit, and
12% (10/82) had two or more follow-up visits in 2019 (implementation). In patients seen by the MDLC, we found an
improved diagnosis of specific lipid conditions (FH (familial hypercholesterolemia), hypertriglyceridemia, and
dyslipidemia), increased prescribing of evidence-based therapies, high rates of medication prior authorization
approvals, and significant reductions in lipid levels by lipid condition subgroup (effectiveness). Over time, the
operations team decided to transition from in-person follow-up to telehealth appointments to increase capacity
and sustain the clinic (maintenance).
(Continued on next page)
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Conclusions: Despite limited reach and adoption of the MDLC, we found a large intervention effect that included
improved diagnosis, increased prescribing of guideline-recommended treatments, and clinically significant
reduction of lipid levels. Attention to factors including solutions to decrease the large burden of unseen referrals,
discussion of the appropriate number and duration of visits, and sustainability of the clinic model could aid in
enhancing the success of the MDLC and improving outcomes for more patients throughout the system.
Keywords: RE-AIM, Hyperlipidemia, Cardiology, Implementation science

Contributions to the literature
 Multidisciplinary lipid clinics (MDLCs) lead to better guideline
concordance, medical management, and patient outcomes
for patients within a large healthcare system.

 Utilizing RE-AIM to analyze a clinical implementation helps
to standardize reporting of outcomes.

 Limited capacity and resources for MDLCs may limit their
ability to meet the patient demand within a large healthcare
system.

Background
The reduction of lipid levels has been shown to prevent
cardiovascular disease (CVD) at individual and population levels [1]. Evidence-based guidelines for lipid therapy exist [2]. While primary care is sufficient for many,
some individuals have medication side effects or underlying severe lipid conditions that make management
more difficult. These individuals require specialized care
in order to achieve lower cholesterol and triglyceride
levels and the corresponding CVD risk reduction
benefit.
Multidisciplinary lipid clinics (MDLCs) focus effort on
reducing CVD risk for individuals with hyperlipidemia
conditions that are complex and hence not easily controlled. Primary care providers (PCPs) refer complex patients to MDLCs with the expertise to more effectively
manage medication options and diagnose underlying
causes of severe dyslipidemia. While MDLCs may vary
in staffing, typical clinical staff includes lipid specialist
physicians, advanced practitioners, pharmacists, dieticians, and genetic counselors working in concert [3–9].
Successful deployment of evidence-based cholesterol
guidelines in these complex patients requires several
clinical skills: nutrition, to improve diet and explain differences in saturated versus unsaturated fats; diagnostic
expertise regarding common and rare cholesterol disorders; and pharmacology, to focus on medication titration, management, and lifelong adherence. Such MDLCs
have been shown to increase the number of individuals
achieving target low-density lipoprotein cholesterol
(LDL-C) goals and improve lipid-lowering medication

adherence, effectively lowering the CVD risk of patients
seen by the MDLC [3, 7].
MDLCs have not previously been evaluated using an
implementation science framework [10]. Applying an
implementation science framework can help standardize
the reporting, examine barriers and facilitators necessary
for a successful MDLC program, and evaluate implementation efforts within a healthcare system. Outcomes
of the implementation science process would include
identifying gaps in care missed by the referral process to
the specialized clinic, improving sustainability, and developing generalizability to other healthcare systems.
When there is an implementation gap, implementation
science can help to understand the causes of the gap.
Reach, effectiveness, adoption, implementation, and
maintenance (RE-AIM) is one framework that has been
used for over 20 years in the planning and evaluation of
interventions [11, 12]. For this study, we conducted an
implementation science evaluation of the first year of a
newly created MDLC utilizing the RE-AIM framework
to provide empirical data not only on program effectiveness, but also on components important to local sustainability and future generalizability and replication.

Methods
Setting

Geisinger is an integrated healthcare system consisting
of multiple hospitals, outpatient facilities, and a health
plan located in 45 counties in central and northeast
Pennsylvania. The system provides care for approximately 1.5 million patients annually. Clinical decisions
and guidance for procedures and treatments are made
by designated clinical teams, and full implementation is
expected by every healthcare provider in the system.
This method not only ensures consistency and highquality care, but also promotes evidence-based care by
reducing unexplained clinical variation. Additionally,
coverage by the health plan is synchronized with clinical
decisions made within the healthcare system to ensure
high-quality care is affordable and accessible to all health
plan members (about a third of Geisinger patients). Geisinger serves a rural, medically underserved, and lowincome population. In Geisinger’s coverage area, 32 of
the 45 counties are designated as rural, and the average
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household income is 15.3% lower than the US average.
Geisinger’s mission and vision are to be a model for
other developing healthcare systems through continued
learning via clinical research [13].
In January 2019, Geisinger implemented an MDLC to
facilitate the translation of evidence-based guidelines [2]
to the management of high-risk lipid conditions. Patients
referred are currently unable to meet cholesterol and triglyceride treatment goals in primary care or cardiology
clinics. The Geisinger MDLC is staffed with a cardiologist boarded in lipidology. The genetic counselor and
pharmacist both have specialized training in lipid conditions. This clinic meets bi-monthly at one clinic location
within the healthcare system. Patients could have traveled from any of Geisinger’s 45 counties within their service area to attend the MDLC.
Population

Any individual within the Geisinger system diagnosed
with or suspected to have a lipid condition can be referred to and seen by the MDLC. A variety of lipid
conditions are evaluated and treated in this clinic, including, but not limited to, familial hypercholesterolemia (FH), hypertriglyceridemia, various rare familial
dyslipidemias, and other unnamed or undiagnosed
dyslipidemias (Table 1) [2].
Clinical implementation

The purpose of the Geisinger MDLC is to increase uptake of guideline-recommended treatment for all lipid
conditions [2]. Prior to implementation of this clinic, individuals with these conditions had to receive specialty
multidisciplinary lipid care outside the Geisinger system
at locations that required significant travel to urban sites
in Pennsylvania for specialized management. Preventive
cardiology leadership within the Heart Institute initiated
the MDLC and sent out an email to the entire Heart
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Institute, and Community and Family Medicine providers inviting them to refer patients. The invitation introduced the MDLC, purpose, details on which
providers were part of this clinic and how to refer. Table
2 details the MDLC implementation strategy using Proctor’s guidelines for defining and specifying implementation strategies [14] and the template for intervention
description and publication checklist.
Data collection and outcomes measured

This study evaluates the first year of MDLC implementation using the RE-AIM framework. Using a pre/poststudy design, clinical outcomes were assessed for all patients 1 year after the implementation of the MDLC.
Outcomes were collected from administrative data, and
clinical information was collected from the electronic
health record (EHR). Two study staff were trained to
search the EHR for laboratory measures, medication
profiles, and appointment visits and performed chart review after each patient appointment.
Reach is measured at the individual level with the
numerator defined as the number of patients seen by
the MDLC who had both a documented lipid condition on their problem list and had been active patients within the healthcare system (i.e., had a
primary care or cardiology visit in 2019). The denominator included those with a problem list diagnosis
for a lipid condition. Patients could be referred to the
MDLC by any provider using an existing general cardiology outpatient referral for lipid management and
were requested to note the MDLC in a comment section. At the time of MDLC implementation, the decision for the system was to use the existing referral
rather than to create a new referral specific to
MDLC. If the MDLC was not specified in the note,
patients could potentially have been seen by any provider with an interest in managing lipid patients.

Table 1 Description of lipid conditions and treatment goals
Condition

Description

Treatment goal

Familial
hypercholesterolemia
(FH)

• Inherited lipid condition

Reduction in LDL-C level

• Lifelong elevations in LDL cholesterol levels lead
to premature ASCVD
• Important to test family members

Hypertriglyceridemia

• Elevated levels of triglycerides

Reduction in triglycerides

• Cholesterol levels can be normal
• At risk for or have had episodes of pancreatitis
• Associated with type II diabetes mellitus
• May encompass inherited hypertriglyceridemia
Dyslipidemia

• Elevated levels of triglycerides and/or cholesterol
• Dyslipidemias that are not FH or
hypertriglyceridemia

According to current guidelines, reduction in the lipid that is
elevated (cholesterol, triglycerides) [2]
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Table 2 Description based on Proctor’s guidelines for specifying implementation strategies: components of the multidisciplinary
lipid clinic
Domain

Description

Name it

Creation of new clinical teams (a multidisciplinary lipid clinic)

Define it

A multidisciplinary clinical team that has complementary roles (i.e., diagnosis and treatment) with lipid expertise that
is formed to improve patient care

Specify it
Actors

Cardiologist
Pharmacist
Genetic counselor

Actions

Cardiologist—evaluates the patient’s symptoms, lifestyle, medications, and past lab results during an initial in-person
visit; recommends a treatment plan; orders subsequent testing; requests follow-up visits as needed
Pharmacist—evaluates the patient’s current medications; offers input/suggests changes to medications; performs
medication reconciliation; completes medication counseling and education; ensures prior authorizations are
submitted
Genetic counselor—evaluates the patient’s past medical and family histories; assesses the patient’s risk; provides pretest genetic counseling; provides genetic testing result disclosure and post-test genetic counseling; discusses cascade
testing of at-risk relatives

Targets of the action

All clinicians—have expertise caring for patients with a high-risk lipid condition and knowledge of guidelinerecommended treatment for lipid conditions
Cardiologist—diagnosis of lipid conditions, monitors clinical symptoms
Pharmacist—optimizes treatment and follow-up on prior authorizations
Genetic counselor—knowledge of familial cardiovascular conditions, improvement of identification methods for
concerning past medical/family history, and reassurance to the patient that the testing results will benefit the patient
no matter if the result is positive or negative

Temporality

Patients should be referred as soon as the provider identifies a patient with a high-risk lipid condition who would
benefit from the evaluation at the clinic. The initial visit to the clinic should take place as soon as scheduling allows
after the patient has been referred. Subsequent visits should be scheduled on an as needed basis.

Dose

Cardiologist—once at an hour-long initial visit. Subsequent visits at 6–8 weeks post-initial visit and further if needed.
The cardiologist will be available to the patient via phone or through patient portal.
Pharmacist—once at an hour-long initial visit. The pharmacist will be available to the patient via phone or patient
portal.
Genetic counselor—once at an hour-long initial visit. The genetic counselor will be available to the patient via phone
or patient portal.

Implementation outcomes
affected

Uptake of guideline-recommended testing and treatment for high-risk lipid clinic patients; adoption of the clinic
among PCPs and other providers; penetration among eligible patients; fidelity to the protocol of the clinic; sustainability of the clinic and its expansion.

Justification

MDLCs improve patient outcomes [3–8]

Effectiveness is stratified to create three clinical patient
lipid subgroups: FH, hypertriglyceridemia, and dyslipidemia because treatment approaches differ by condition.
The final diagnosis was extracted from cardiologist
documentation after all relevant information was obtained. The effectiveness measure chosen for this study
was the change in lipid levels assessed using a baseline
lipid value either from the initial MDLC visit or the
most recent lipid panel result prior to the initial MDLC
follow-up visit compared with the value from the most
recent MDLC visit. Patients without a lipid panel in their
health records were documented as having no prior lipid
measurements. The most recent lipid panel was recorded as post-MDLC measurement, unless that measurement was the pre-MDLC value. All post-MDLC

measurements were at least 1 month after their initial
visit date.
Adoption has two metrics. Any PCP or cardiologist
who saw a patient with a lipid condition documented on
their problem list diagnoses in 2019 was included in the
analyses. The percent of eligible providers referring to
the MDLC was calculated as the number of providers
making a referral divided by the total number of eligible
providers multiplied by 100. The percent of eligible patients referred per provider—as measured by having a
lipid condition in the problem list—was calculated as the
number referred over the total number of lipid patients
managed by that provider.
Implementation is measured at the patient level. The
numerator is the number of patients with multiple visits,
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and the denominator is the number of patients seen in
2019. The percentage of patients who underwent genetic
testing and medication use details were reported using
descriptive statistics.
Maintenance, for this study, is reported as the current
and potential for sustaining the MDLC in the future.
Statistical analysis

Descriptive statistics were used for the demographics of
both the study cohort and three subgroups. Continuous
variables were analyzed using the Kruskal-Wallis test,
and categorical variables were analyzed using a Fisher
exact test. We reported the mean ± SD and median
(range) of lipid levels for all subgroups and used the
Wilcoxon signed-rank test to detect any differences in
lipid levels before and after for each subgroup.
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Hypertriglyceridemia

Lipid levels were available for comparison before and
after MDLC visits in a subset of patients (n = 4) and
showed a 467-mg/dL reduction in average triglycerides
(Table 4). Of the 4 patients with pre- and post-values,
only a quarter (1/4) had a triglyceride level less than 150
mg/dL prior to a visit with the MDLC; however, 75% (3/
4) met this goal afterwards.
Uncharacterized dyslipidemia

Lipid levels were available for comparison before and
after MDLC visits in a subset of patients (n = 21) and
showed a 48-mg/dL reduction in average LDL-C (<
0.001) and reduction in other lipid values (Table 4). Of
the 21 patients, 38% (8/21) had an LDL-C less than 100
mg/dL prior to a visit with the MDLC; however, 71%
(15/21) met this goal afterwards.

Results
Reach

Adoption

Of the 452,748 unique patients who had a visit to the
healthcare system in 2019, 32% (143,154/452,748) had a
diagnosis of a lipid condition on their problem list.
There were 420 referrals received for the MDLC in 2019
out of the 143,154 individuals with a lipid condition. Of
those 420 referrals, 3 referenced the “MDLC” specifically
and 92 referenced the “lipid clinic.” There were 83 patients scheduled and seen by the MDLC in 2019 (20% of
those referred). Of those 83 patients, 1 patient was selfreferred, and 4 patients did not have a primary care or
cardiology visit in 2019 or lipid condition diagnosis
code.

Of the 796 active PCP or cardiologists in 2019, 19%
(148/796) referred patients to the MDLC. The average
percent of eligible patient referrals from active providers
was 0.25% (SD 3.75%). There was an average of 35 patient referrals per month (SD 12) to the MDLC. Referrals to MDLC were also received from another 48
providers outside of the targeted cardiologists and PCPs
(genetic counselors, pharmacists, critical care providers)
or from providers whose patients did not have a diagnosed lipid condition on their problem list.

Effectiveness

Of the 83 patients seen in the MDLC in 2019, 82 were
alive at the time of analysis and are presented in the results. Guideline recommendations for management vary
based on lipid condition. The MDLC patient population
was stratified for analysis based on lipid diagnosis: familial hypercholesterolemia, hypertriglyceridemia, and
uncharacterized dyslipidemia. Of those 82 patients, 29%
(24/82) had a clinical or genetic diagnosis of (FH), 20%
(16/82) had hypertriglyceridemia, and 51% (42/82) had
uncharacterized dyslipidemia. Demographics of these
populations are described in Table 3.
Familial hypercholesterolemia

Lipid levels were available for comparison before and
after MDLC visits in a subset of patients (n = 12) and
showed a 79-mg/dL reduction in average LDL-C (P <
0.001) and reduction in other lipid values (Table 4). Of
the 12 patients with pre- and post-values, only 17% (2/
12) had an LDL-C less than 100 mg/dL prior to a visit
with the MDLC; however, 75% (9/12) met this goal
afterwards.

Implementation

At the patient level, 50% (41/82) of patients who
attended the MDLC had at least one follow-up visit with
the MDLC, with 12% (10/82) having two or more
follow-up visits in 2019. The 50% (41/82) of patients
who only had one visit were more likely to have been
seen later in 2019 (October through December). Patientand provider-level implementation outcomes of genetic
testing and prescribing of guideline-recommended treatment are described based on lipid subgroup.
Familial hypercholesterolemia

Six of the 24 individuals with FH had prior positive genetic testing for the condition. Those who did not have a
prior genetic testing result had testing ordered at the
MDLC. Genetic testing ordered through the MDLC (n =
18) yielded 5 positive results, 2 variants of unknown significance, and 5 negative results. Six genetic tests are still
pending (e.g., order not signed, order expired, active
order but sample has not yet been drawn). At the initial
MDLC visit, 17 (71%) patients were prescribed at least
one medication (e.g., prescribed by some other provider
prior to getting to MDLC). Of the 24 patients in the FH
subgroup, 1 (4%) had no changes to their medication
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Table 3 Baseline demographics for all patients seen in the MDLC
All patients, N = 82
(ref)

Familial hypercholesterolemia, N
= 24

Dyslipidemia, N =
42

Hypertriglyceridemia, N
= 16

P
value

Age in years

56 ± 15

53 ± 16

62 ± 13

45 ± 13

<
0.001

Male

42 (51%)

6 (25%)

25 (60%)

11 (69%)

0.007

BMI

31 ± 8

27 ± 6

32 ± 7

34 ± 10

Never

46 (56%)

16 (67%)

20 (48%)

10 (62%)

Former

28 (34%)

5 (21%)

18 (43%)

5 (31%)

Current

8 (10%)

3 (12%)

4 (9%)

1 (7%)

Problem list diagnosis of
CAD

36 (44%)

6 (25%)

26 (62%)

4 (25%)

0.004

Problem list diagnosis of
PVD

7 (9%)

2 (8%)

5 (12%)

0

0.502

No reported MIs

67 (82%)

22 (92%)

30 (71%)

15 (94%)

0.243

41 (50%)

12 (50%)

16 (38%)

13 (81%)

Tobacco status

0.436

Number of appointments

0.011

1
2

31 (38%)

11 (46%)

19 (45%)

1 (7%)

3 or more

10 (12%)

1 (4%)

7 (17%)

2 (12%)

BMI body mass index, CAD coronary artery disease, PVD peripheral vascular disease, MI myocardial infarction

regimen. This patient did not have any medications preor post-MDLC due to pregnancy, which impacts the use
of lipid-lowering therapy. The 23 (96%) patients who
had a change to their medication regimen fell into one
or more of the following categories: 21 patients had an

intensification of their medication regimens including
starting a medication, increasing the dose of a medication, or addition of a new medication; 1 had a decrease
in their dose of a medication; and 10 had other changes
including discontinuations or switches within a

Table 4 Lipid levels pre/post-implementation of the MDLC
Baseline
N

Post
Mean ± SD

Median (range)

N

Mean ± SD

Median (range)

P
value

Familial hypercholesterolemia (N = 12)
Total cholesterol

12

237 ± 72

247 (133, 361)

12

162 ± 71

150 (86, 346)

< 0.001

HDL-C

12

53 ± 14

53 (25, 79)

12

55 ± 11

57 (33, 73)

0.637

LDL-C

12

163 ± 69

166 (71, 296)

12

87 ± 70

84 (9, 279)

< 0.001

TG

12

118 ± 59

118 (34, 238)

12

96 ± 44

90 (37, 173)

0.077

Non-HDL-C

12

184 ± 69

186 (87, 316)

12

106 ± 73

95 (26, 302)

< 0.001

Total cholesterol

21

213 ± 68

222 (115, 376)

22

168 ± 67

152 (79, 371)

< 0.001

HDL-C

21

44 ± 15

40 (25, 83)

21

46 ± 18

40 (27, 105)

0.223

LDL-C

21

135 ± 67

135 (48, 277)

21

87 ± 56

70 (2, 243)

< 0.001

TG

21

226 ± 182

176 (69, 927)

21

204 ± 199

140 (79, 1002)

0.266

Non-HDL-C

21

169 ± 63

184 (65, 305)

21

121 ± 64

105 (34, 312)

< 0.001

264 (146, 284)

4

162 ± 47

148 (121, 230)

NA

Dyslipidemia (N = 21)

Hypertriglyceridemia (N = 4)
Total cholesterol

4

239 ± 63

HDL-C

4

24 ± 9

27 (11, 31)

4

28 ± 12

32 (11, 37)

NA

LDL-C

4

73 ± 50

84 (4, 121)

3

47 ± 32

65 (10, 65)

NA

TG

4

1123 ± 452

975 (759, 1784)

4

656 ± 613

428 (232, 1536)

NA

Non-HDL-C

4

215 ± 54

236 (135, 254)

4

134 ± 45

112 (110, 202)

NA

HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglycerides
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medication class. Fourteen of the 24 individuals with FH
were prescribed medications for which their insurance
required a prior authorization. A total of 16 prior authorizations were submitted (3 individuals had prior authorizations submitted for both PCSK9 inhibitors and
icosapent ethyl or for two PCSK9 inhibitors). Of the 16
medication prior authorizations submitted by the
MDLC, 88% (14/16) were approved (12 for PCSK9 inhibitors and 2 for icosapent ethyl) and 13% (2/16) were
denied for PCSK9 inhibitors.
Hypertriglyceridemia

None of the 16 individuals attending MDLC diagnosed
with hypertriglyceridemia had prior genetic testing. Genetic testing was ordered on 14 of the 16 individuals
(88%) and identified 1 positive result for a variant associated with familial lipoprotein lipase deficiency, 2 variants
of unknown significance, and 6 negative results; 3 tests
are pending, and 2 were not completed. At the initial
MDLC visit, 15 (94%) patients were currently prescribed
at least one medication to treat their hypertriglyceridemia. Of the 16 patients in the hypertriglyceridemia
subgroup, 3 (19%) had no changes to their medication
regimen. The 13 (81%) patients who had a change to
their medication regimen fell into one or more of the
following categories: 10 patients had an intensification of
their medication regimens including starting a medication, increasing the dose of a medication, or addition of
a new medication; 1 had a decrease in their dose of a
medication; and 4 had other changes including discontinuations or switches within a medication class. One
person that switched between medication classes was
the reconciliation of a drug-drug interaction to prevent
harm to the patient. At the time of analysis, 16 (100%)
of the 16 patients in the hypertriglyceridemia subgroup
after being seen by the MDLC were prescribed a medication for the treatment of hypertriglyceridemia. Three
of the 16 individuals with hypertriglyceridemia were prescribed medications by the MDLC for which their insurance required a prior authorization, resulting in a total
of 3 prior authorizations submitted. All were approved
(2 were for PCSK9 inhibitors and 1 for icosapent ethyl).
Uncharacterized dyslipidemia

None of the 42 individuals with dyslipidemia had prior
genetic testing for the condition. Genetic testing was ordered by MDLC for 31 (74%) patients and found no
positive results, 24 negative results, 6 tests are pending,
and 1 was canceled by the patient due to cost. Genetic
testing was not ordered for 11 individuals. At the initial
MDLC visit, 32 (76%) patients were prescribed at least
one medication to treat their dyslipidemia. Of the 42 patients in the dyslipidemia subgroup, 7 (17%) had no
changes to their medication regimen. The 35 (81%)

Page 7 of 10

patients who had a change to their medication regimen
fell into one or more of the following categories: 31 patients had an intensification of their medication regimens including starting a medication, increasing the
dose of a medication, or addition of a new medication; 1
had a decrease in their dose of a medication; and 16 had
other changes including discontinuations or switches
within a medication class. Eighteen of the 42 individuals
with dyslipidemia were prescribed medications for which
their insurance required prior authorization. A total of
18 prior authorizations were submitted. Of those 18, 16
were approved (for PCSK9 inhibitors), 1 was denied for
icosapent ethyl, and 1 had an unknown status for a
PCSK9 inhibitor.
Maintenance

In monthly meetings with the MDLC clinic providers
and Heart Institute leadership and administration, we
discussed the transition from traditional in-person
follow-up visits to telehealth appointments. The rationale for this transition was to improve capacity due to a
limited number of available appointments per clinic day
and would increase access as individuals would have the
opportunity to be seen virtually, either at home or at a
clinic site near their home. Additionally, there was a discussion for the need for a telehealth platform, training of
schedulers to know where and when to book these appointments, where and how the MDLC providers would
join the telehealth visit and obtain access for all providers, and discuss methods for documenting these types
of visits. Additionally, a recent pandemic, COVID-19,
necessitated the use of telemedicine throughout Geisinger, but this merely accelerated the transition that
was already planned for the MDLC.

Discussion
In our evaluation of the first year after implementing a
new care model, we found there are many individuals
within our system with lipid conditions, but only a small
number have been referred to the MDLC (0.25%), indicating additional implementation strategies may be
needed to improve the reach of the MDLC to improve
patient care. At present, in the total population of patients with lipid disorders, we do not know how many
would be eligible for referral based on medication intolerance or failure to achieve the lipid treatment goal.
Only by evaluating this can the true care gap be evaluated and used to develop strategies to expand referrals.
We found MDLC improved patient prognosis based on
risk stratification, increase in guideline-recommended
treatments prescribed, and clinically significant lowering
of targeted lipid levels necessary for the prevention of future CVD events. A reduction of 40 mg/dL of LDL-C for
individuals with cholesterol conditions is thought to
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reduce CV events by 20% which is clinically significant
and is an accepted intermediate outcome per guidelines
[15]. In patients with FH seen through the MDLC, the
mean reduction in LDL-C was 79 mg/dL, which is predicted to reduce CV events by 40%. In addition, through
MDLC, the number of patients achieving a target of
LDL-C below 100 mg/dL increased from 15 to 69%, a
more than 4-fold increase.
Based on the referral volume after 1 year of MDLC
implementation with referrals from only PCPs and cardiologists, we have shown (1) a need for the MDLC in the
Geisinger system, (2) a significant clinical impact on
those patients managed by the MDLC, and (3) an enormous care gap with only 0.25% of eligible patients being
seen through MDLC reducing the potential impact on
CV event prevention.
Barriers to MDLC sustainability included the inability
of the MDLC to see all patients that were referred in the
first year. Another barrier was not specifying the MDLC
in the notes section of the referral by referring providers.
Due to these barriers, some patients were not seen by
the MDLC but by the designated lipid expert in their
corresponding region which led to some frustration by
patients and providers who were expecting to be evaluated by a team of lipid experts from multiple disciplines.
Facilitators of sustainability included the large cadre of
providers who referred patients. The MDLC provided a
more refined clinical diagnosis and treatment plan for
patients. We believe that this will incentivizes providers
to continue to refer severe lipid disorder patients that
they are unable to diagnose.
A systematic approach to implementation and continual evaluation of implementation process outcomes and
contextual factors is important to implementing these
types of programs within healthcare systems. To that
end, team members and administrative staff have discussed initiating telehealth appointments as a potential
solution for the sustainability of these types of programs
in general and the MDLC specifically. By utilizing telehealth, patients would be able to join at their home or
drive to a local clinic to connect with the providers at
the MDLC located at a central hub. This model could be
generalized to other healthcare systems that have large
service areas. The COVID-19 pandemic resulted in a
system-wide move to telemedicine visits, eliminating
many barriers that might have otherwise delayed the
implementation.
Other MDLCs have found similar clinical effectiveness
outcomes to our clinic [7, 8, 16]. For MDLCs to improve
the health of the targeted population, they must first
reach the intended individuals. While the existence of an
MDLC is helpful, it is not sufficient to ensure utilization
of its services. Most of these MDLCs have been implemented within academic medical centers [10] with fewer
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in healthcare systems, mostly in Veteran’s Affairs [8, 16]
or community medical centers [17]. However, it is unclear from these studies the potential impact MDLCs
have had on reach within their patient catchment areas
due to lack of description or analysis on the process for
referrals and number of patients with lipid conditions in
these systems. To improve generalizability to other
healthcare systems, it is important to understand contextual factors associated with the implementation of a
MDLC.
It is widely accepted in implementation science that
simply rolling out a new professional guideline or making a new model of care available is insufficient to lead
to practice change that will impact patient or population
health outcomes [18]. Often, sufficient details are lacking
to replicate the implementation strategies utilized for
the evidence-based intervention or new care model [14].
Therefore, evaluation of multi-level outcomes related to
process and context as well as patient outcomes is necessary when implementing interventions in the real
world [19].
Implementation science frameworks have rarely been
applied in the field of lipidology or FH [20]. However,
their use and benefit have been demonstrated in the implementation of other chronic disease programs such as
diabetes control [21]. Using frameworks such as REAIM will help lipidologists, and others implementing
MDLCs, understand the full impact of their programs
and where the barriers and facilitators to access or care
exist [22, 23]. In addition, studies like ours will improve
the generalizability of these programs to other sites.
This study has a few limitations. Most patients were
able to see all providers described within the MDLC;
however, there were rare circumstances where one provider might have been unavailable. A specific outpatient
referral for the MDLC was not created within our system, though dependent upon the success and volume of
this clinic, one can be created in the future. The number
of patients seen and followed up in the recommended
time frame with the MDLC was limited by clinical location and capacity (one location in the region and twice
per month periodicity). However, the Geisinger catchment area spans 45 of Pennsylvania’s 67 counties making
it over a 2-h drive for some individuals to reach the
current MDLC location. Some individuals seen in the
MDLC require multiple visits for complex diagnoses or
medication changes, thus limiting the availability of appointment slots for new patients. In addition, we used a
pre/post-study design to analyze our data which comes
with limitations including the possibility of experiencing
a Hawthorne effect. In our analyses, we used a follow-up
period defined by time since the clinic was implemented;
therefore, patients seen earlier after implementation had
longer follow-up intervals than those seen later in the

Jones et al. Implementation Science Communications

(2021) 2:32

year. Additional analyses conducted farther out from
MDLC implementation are needed with larger samples
of individuals with a standard follow-up period (e.g., 1year post-visit). Finally, by limiting to the 1-year period
after implementation, some individuals with pending
genetic test results in the dyslipidemia category may
move into a different category once the test results are
received.

Conclusions
Severe lipid conditions require dedicated care for identification, early intervention, and management. Individuals
treated at the Geisinger MDLC show improved clinical
outcomes 1 year after MDLC implementation. More attention is needed regarding context, solutions to decrease unseen referrals, appropriate number and
duration of MDLC visits, and sustainability. Attention to
these things will help determine the impact of MDLC on
patient outcomes and improve reach, adoption, sustainability, and replication within other healthcare settings.
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